Valentin Derangère INSERM U866, France
2 protocols

Mélanie Bruchard INSERM U866, France
2 protocols

Frédérique Végran INSERM U866, France
2 protocols

François Ghiringhelli
  • INSERM U866, France
  • 2 Author merit


Ph.D. in Cellular Biology and Immunology, Dijon, France, 2005

Current position

Professor in Medical Oncology and Director of an INSERM research team (Chemotherapy, Lipids Metabolism and Antitumor Immune Response), Faculté de Médecine – CGFL, Dijon, France

Publications (since 2013)

  1. Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., Poillot, M. L., Arveux, P., Delaloge, S., Andre, F., Zitvogel, L. and Kroemer, G. (2016). The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy 12(5): 864-875.
  2. Thibaudin, M., Chaix, M., Boidot, R., Végran, F., Derangère, V., Limagne, E., Berger, H., Ladoire, S., Apetoh, L. and Ghiringhelli, F. (2016). Human ectonucleotidase-expressing CD25 Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Oncoimmunology 5(1): e1055444.
  3. Fluckiger, A., Dumont, A., Derangère, V., Rébé, C., de Rosny, C., Causse, S., Thomas, C., Apetoh, L., Hichami, A., Ghiringhelli, F. and Rialland, M. (2016). Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFalpha. Oncogene
  4. Derangère, V., Fumet, J. D., Boidot, R., Bengrine, L., Limagne, E., Chevriaux, A., Vincent, J., Ladoire, S., Apetoh, L., Rébé, C. and Ghiringhelli, F. (2016). Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget 7(8): 9309-9321.
  5. Gobbo, J., Marcion, G., Cordonnier, M., Dias, A. M., Pernet, N., Hammann, A., Richaud, S., Mjahed, H., Isambert, N., Clausse, V., Rébé, C., Bertaut, A., Goussot, V., Lirussi, F., Ghiringhelli, F., de Thonel, A., Fumoleau, P., Seigneuric, R. and Garrido, C. (2016). Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. J Natl Cancer Inst 108(3).
  6. Boidot, R., Chevrier, S., Julie, V., Ladoire, S. and Ghiringhelli, F. (2016). HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report. Int J Colorectal Dis 31(6): 1245-1246.
  7. Bullón, P., Alcocer-Gómez, E., Carrión, A. M., Marín-Aguilar, F., Garrido-Maraver, J., Román-Malo, L., Ruiz-Cabello, J., Culic, O., Ryffel, B., Apetoh, L., Ghiringhelli, F., Battino, M., Sánchez-Alcazar, J. A. and Cordero, M. D. (2016). AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome. Antioxid Redox Signal 24(3): 157-170.
  8. Nani, A., Belarbi, M., Ksouri-Megdiche, W., Abdoul-Azize, S., Benammar, C., Ghiringhelli, F., Hichami, A. and Khan, N. A. (2015). Effects of polyphenols and lipids from Pennisetum glaucum grains on T-cell activation: modulation of Ca(2+) and ERK1/ERK2 signaling. BMC Complement Altern Med 15: 426.
  9. Courcet, E., Beltjens, F., Charon-Barra, C., Guy, F., Orry, D., Ghiringhelli, F. and Arnould, L. (2015). [An IgG4-related pancreatitis mimicking an adenocarcinoma: A case report]. Ann Pathol 35(6): 511-514.
  10. Ladoire, S., Penault-Llorca, F., Senovilla, L., Dalban, C., Enot, D., Locher, C., Prada, N., Poirier-Colame, V., Chaba, K., Arnould, L., Ghiringhelli, F., Fumoleau, P., Spielmann, M., Delaloge, S., Poillot, M. L., Arveux, P., Goubar, A., Andre, F., Zitvogel, L. and Kroemer, G. (2015). Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy 11(10): 1878-1890.
  11. Ghiringhelli, F., Vincent, J., Beltjens, F., Bengrine, L. and Ladoire, S. (2015). Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Invest New Drugs 33(6): 1263-1266.
  12. Bruchard, M., Boidot, R., Ghiringhelli, F. and Végran, F. (2015). Transcriptome analysis of TH2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice. Genom Data 5: 314-315.
  13. Courtaut, F., Derangère, V., Chevriaux, A., Ladoire, S., Cotte, A. K., Arnould, L., Boidot, R., Rialland, M., Ghiringhelli, F. and Rébé, C. (2015). Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRbeta subcellular localization. Oncotarget 6(29): 26651-26662.
  14. Alentorn, A., Dehais, C., Ducray, F., Carpentier, C., Mokhtari, K., Figarella-Branger, D., Chinot, O., Cohen-Moyal, E., Ramirez, C., Loiseau, H., Elouahdani-Hamdi, S., Beauchesne, P., Langlois, O., Desenclos, C., Guillamo, J. S., Dam-Hieu, P., Ghiringhelli, F., Colin, P., Godard, J., Parker, F., Dhermain, F., Carpentier, A. F., Frenel, J. S., Menei, P., Bauchet, L., Faillot, T., Fesneau, M., Fontaine, D., Motuo-Fotso, M. J., Vauleon, E., Gaultier, C., Le Guerinel, C., Gueye, E. M., Noel, G., Desse, N., Durando, X., Barrascout, E., Wager, M., Ricard, D., Carpiuc, I., Delattre, J. Y., Idbaih, A. and Network, P. (2015). Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology 85(15): 1325-1331.
  15. Rébé, C. and Ghiringhelli, F. (2015). Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies? Future Oncol.
  16. Alcocer-Gómez, E., Ulecia-Morón, C., Marín-Aguilar, F., Rybkina, T., Casas-Barquero, N., Ruiz-Cabello, J., Ryffel, B., Apetoh, L., Ghiringhelli, F., Bullón, P., Sánchez-Alcazar, J. A., Carrión, A. M. and Cordero, M. D. (2015). Stress-Induced Depressive Behaviors Require a Functional NLRP3 Inflammasome. Mol Neurobiol.
  17. Bruchard, M., Rebé, C., Derangère, V., Togbé, D., Ryffel, B., Boidot, R., Humblin, E., Hamman, A., Chalmin, F., Berger, H., Chevriaux, A., Limagne, E., Apetoh, L., Vegran, F. and Ghiringhelli, F. (2015). The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol 16(8): 859-870.
  18. Apetoh, L., Ladoire, S., Coukos, G. and Ghiringhelli, F. (2015). Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 26(9): 1813-1823.
  19. Etienne-Grimaldi, M. C., Boyer, J. C., Thomas, F., Quaranta, S., Picard, N., Loriot, M. A., Narjoz, C., Poncet, D., Gagnieu, M. C., Ged, C., Broly, F., Le Morvan, V., Bouquié, R., Gaub, M. P., Philibert, L., Ghiringhelli, F., Le Guellec, C., Collective work by Groupe de Pharmacologie Clinique, O. and French Réseau National de Pharmacogénétique, H. (2015). UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol 29(3): 219-237.
  20. Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., Bracci, L., Breckpot, K., Brough, D., Buqué, A., Castro, M. G., Cirone, M., Colombo, M. I., Cremer, I., Demaria, S., Dini, L., Eliopoulos, A. G., Faggioni, A., Formenti, S. C., Fučíková, J., Gabriele, L., Gaipl, U. S., Galon, J., Garg, A., Ghiringhelli, F., Giese, N. A., Guo, Z. S., Hemminki, A., Herrmann, M., Hodge, J. W., Holdenrieder, S., Honeychurch, J., Hu, H. M., Huang, X., Illidge, T. M., Kono, K., Korbelik, M., Krysko, D. V., Loi, S., Lowenstein, P. R., Lugli, E., Ma, Y., Madeo, F., Manfredi, A. A., Martins, I., Mavilio, D., Menger, L., Merendino, N., Michaud, M., Mignot, G., Mossman, K. L., Multhoff, G., Oehler, R., Palombo, F., Panaretakis, T., Pol, J., Proietti, E., Ricci, J. E., Riganti, C., Rovere-Querini, P., Rubartelli, A., Sistigu, A., Smyth, M. J., Sonnemann, J., Spisek, R., Stagg, J., Sukkurwala, A. Q., Tartour, E., Thorburn, A., Thorne, S. H., Vandenabeele, P., Velotti, F., Workenhe, S. T., Yang, H., Zong, W. X., Zitvogel, L., Kroemer, G. and Galluzzi, L. (2014). Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3(9): e955691.
  21. Guion-Dusserre, J. F., Lorgis, V., Vincent, J., Bengrine, L. and Ghiringhelli, F. (2015). FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 21(7): 2096-2101.
  22. Madouri, F., Guillou, N., Fauconnier, L., Marchiol, T., Rouxel, N., Chenuet, P., Ledru, A., Apetoh, L., Ghiringhelli, F., Chamaillard, M., Zheng, S. G., Trovero, F., Quesniaux, V. F., Ryffel, B. and Togbe, D. (2015). Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. J Mol Cell Biol 7(4): 351-365.
  23. Mirjolet, C., Boidot, R., Saliques, S., Ghiringhelli, F., Maingon, P. and Créhange, G. (2015). The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy. Cancer Treat Rev 41(4): 354-360.
  24. Aparicio, T., Linot, B., Le Malicot, K., Bouché, O., Boige, V., Francois, E., Ghiringhelli, F., Legoux, J. L., Ben Abdelghani, M., Phelip, J. M., Faroux, R., Dahan, L., Taieb, J. and Bedenne, L. (2015). FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802). Dig Liver Dis 47(4): 271-272.
  25. Végran, F., Apetoh, L. and Ghiringhelli, F. (2015). Th9 cells: a novel CD4 T-cell subset in the immune war against cancer. Cancer Res 75(3): 475-479.
  26. Jary, M., Vernerey, D., Lecomte, T., Dobi, E., Ghiringhelli, F., Monnien, F., Godet, Y., Kim, S., Bouché, O., Fratte, S., Goncalves, A., Leger, J., Queiroz, L., Adotevi, O., Bonnetain, F. and Borg, C. (2015). Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma. Cancer Epidemiol Biomarkers Prev 24(3): 603-612.
  27. Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J. M., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J. P., Agostinis, P., Apte, R. N., Aranda, F., Ayyoub, M., Beckhove, P., Blay, J. Y., Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, V., Clayton, A., Colombo, M. P., Coussens, L., Dhodapkar, M. V., Eggermont, A. M., Fearon, D. T., Fridman, W. H., Fučíková, J., Gabrilovich, D. I., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., Hosmalin, A., Jager, D., Kalinski, P., Kärre, K., Kepp, O., Kiessling, R., Kirkwood, J. M., Klein, E., Knuth, A., Lewis, C. E., Liblau, R., Lotze, M. T., Lugli, E., Mach, J. P., Mattei, F., Mavilio, D., Melero, I., Melief, C. J., Mittendorf, E. A., Moretta, L., Odunsi, A., Okada, H., Palucka, A. K., Peter, M. E., Pienta, K. J., Porgador, A., Prendergast, G. C., Rabinovich, G. A., Restifo, N. P., Rizvi, N., Sautes-Fridman, C., Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M. J., Speiser, D. E., Spisek, R., Srivastava, P. K., Talmadge, J. E., Tartour, E., Van Der Burg, S. H., Van Den Eynde, B. J., Vile, R., Wagner, H., Weber, J. S., Whiteside, T. L., Wolchok, J. D., Zitvogel, L., Zou, W. and Kroemer, G. (2014). Classification of current anticancer immunotherapies. Oncotarget 5(24): 12472-12508.
  28. Pagès, P. B., Derangere, V., Bouchot, O., Magnin, G., Charon-Barra, C., Lokiec, F., Ghiringhelli, F. and Bernard, A. (2015). Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs. Eur J Cardiothorac Surg 48(2): 228-235.
  29. Colin, D. J., Limagne, E., Ragot, K., Lizard, G., Ghiringhelli, F., Solary, É., Chauffert, B., Latruffe, N. and Delmas, D. (2014). The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models. Cell Death Dis 5: e1533.
  30. Figarella-Branger, D., Mokhtari, K., Colin, C., Uro-Coste, E., Jouvet, A., Dehais, C., Carpentier, C., Villa, C., Maurage, C. A., Eimer, S., Polivka, M., Vignaud, J. M., Laquerriere, A., Sevestre, H., Lechapt-Zalcman, E., Quintin-Roué, I., Aubriot-Lorton, M. H., Diebold, M. D., Viennet, G., Adam, C., Loussouarn, D., Michalak, S., Rigau, V., Heitzmann, A., Vandenbos, F., Forest, F., Chiforeanu, D., Tortel, M. C., Labrousse, F., Chenard, M. P., Nguyen, A. T., Varlet, P., Kemeny, J. L., Levillain, P. M., Cazals-Hatem, D., Richard, P., Delattre, J. Y. and Network, P. (2015). Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. Brain Pathol 25(4): 418-428.
  31. Ghiringhelli, F. and Apetoh, L. (2015). Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives. Biomed J 38(2): 111-116.
  32. Facy, O., Combier, C., Poussier, M., Magnin, G., Ladoire, S., Ghiringhelli, F., Chauffert, B., Rat, P. and Ortega-Deballon, P. (2015). High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery 157(1): 72-78.
  33. Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R. and Zitvogel, L. (2015). Gut microbiome and anticancer immune response: really hot Sh*t! Cell Death Differ 22(2): 199-214.
  34. Mignot, G., Hervieu, A., Vabres, P., Dalac, S., Jeudy, G., Bel, B., Apetoh, L. and Ghiringhelli, F. (2014). Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients. PLoS One 9(8): e105907.
  35. Derangère, V., Chevriaux, A., Courtaut, F., Bruchard, M., Berger, H., Chalmin, F., Causse, S. Z., Limagne, E., Végran, F., Ladoire, S., Simon, B., Boireau, W., Hichami, A., Apetoh, L., Mignot, G., Ghiringhelli, F. and Rébé, C. (2014). Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells. Cell Death Differ 21(12): 1914-1924.
  36. Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R. and Zitvogel, L. (2014). Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. Cancer Res 74(16): 4217-4221.
  37. Chaix, M., Vincent, J., Lorgis, V. and Ghiringhelli, F. (2014). FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. Oncology 87(3): 148-158.
  38. Chevrier, S., Arnould, L., Ghiringhelli, F., Coudert, B., Fumoleau, P. and Boidot, R. (2014). Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations. Int J Oncol 45(3): 1167-1174.
  39. Boyer, J. C., Etienne-Grimaldi, M. C., Thomas, F., Quaranta, S., Picard, N., Loriot, M. A., Poncet, D., Gagnieu, M. C., Ged, C., Broly, F., Le Morvan, V., Bouquié, R., Gaub, M. P., Philibert, L., Ghiringhelli, F. and Le Guellec, C. (2014). [Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan]. Bull Cancer 101(6): 533-553.
  40. Végran, F., Berger, H., Boidot, R., Mignot, G., Bruchard, M., Dosset, M., Chalmin, F., Rébé, C., Dérangère, V., Ryffel, B., Kato, M., Prévost-Blondel, A., Ghiringhelli, F. and Apetoh, L. (2014). The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 15(8): 758-766.
  41. Ghiringhelli, F., Hennequin, A., Drouillard, A., Lepage, C., Faivre, J. and Bouvier, A. M. (2014). Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. Dig Liver Dis 46(9): 854-858.
  42. Bruchard, M. and Ghiringhelli, F. (2014). [Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets]. Bull Cancer 101(6): 605-607.
  43. Jary, M., Ghiringhelli, F., Jacquin, M., Fein, F., Nguyen, T., Cleau, D., Nerich, V., El Gani, M., Mathieu, P., Valmary-Degano, S., Arnould, L., Lassabe, C., Lamfichekh, N., Fratté, S., Paget-Bailly, S., Bonnetain, F., Borg, C. and Kim, S. (2014). Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Cancer Chemother Pharmacol 74(1): 141-150.
  44. Ghiringhelli, F., Lorgis, V., Vincent, J., Ladoire, S. and Guiu, B. (2013). Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience. Chemotherapy 59(5): 354-360.
  45. Bruchard, M. and Ghiringhelli, F. (2014). [Tumor microenvironment: regulatory cells and immunosuppressive cytokines]. Med Sci (Paris) 30(4): 429-435.
  46. Figarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Forest, F., Maurage, C. A., Vignaud, J. M., Polivka, M., Lechapt-Zalcman, E., Eimer, S., Viennet, G., Quintin-Roué, I., Aubriot-Lorton, M. H., Diebold, M. D., Loussouarn, D., Lacroix, C., Rigau, V., Laquerriere, A., Vandenbos, F., Michalak, S., Sevestre, H., Peoch, M., Labrousse, F., Christov, C., Kemeny, J. L., Chenard, M. P., Chiforeanu, D., Ducray, F., Idbaih, A. and Network, P. (2014). Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro Oncol 16(9): 1244-1254.
  47. Chauffert, B., Feuvret, L., Bonnetain, F., Taillandier, L., Frappaz, D., Taillia, H., Schott, R., Honnorat, J., Fabbro, M., Tennevet, I., Ghiringhelli, F., Guillamo, J. S., Durando, X., Castera, D., Frenay, M., Campello, C., Dalban, C., Skrzypski, J. and Chinot, O. (2014). Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFdagger. Ann Oncol 25(7): 1442-1447.
  48. Rambach, L., Bertaut, A., Vincent, J., Lorgis, V., Ladoire, S. and Ghiringhelli, F. (2014). Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. World J Gastroenterol 20(6): 1565-1573.
  49. Ghiringhelli, F., Bichard, D., Limat, S., Lorgis, V., Vincent, J., Borg, C., Berthou, J., Orry, D., Ortega-Deballon, P., Lakkis, Z., Facy, O., Heyd, B., Rat, P., Nerich, V. and Ladoire, S. (2014). Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection. Ann Surg Oncol 21(5): 1632-1640.
  50. Ladoire, S., Dalban, C., Roché, H., Spielmann, M., Fumoleau, P., Levy, C., Martin, A. L., Ecarnot, F., Bonnetain, F. and Ghiringhelli, F. (2014). Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials. Eur J Cancer 50(3): 506-516.
  51. Reyes-Botero, G., Dehais, C., Idbaih, A., Martin-Duverneuil, N., Lahutte, M., Carpentier, C., Letouzé, E., Chinot, O., Loiseau, H., Honnorat, J., Ramirez, C., Moyal, E., Figarella-Branger, D., Ducray, F. and Network, P. (2014). Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 16(5): 662-670.
  52. Mignot, G., Bugaut, H. and Ghiringhelli, F. (2013). Immune ambivalence: The schizophrenic bleomycin. Oncoimmunology 2(9): e25737.
  53. Ghiringhelli, F. and Apetoh, L. (2014). The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. Expert Rev Clin Immunol 10(1): 19-30.
  54. Ladoire, S., Hannani, D., Vetizou, M., Locher, C., Aymeric, L., Apetoh, L., Kepp, O., Kroemer, G., Ghiringhelli, F. and Zitvogel, L. (2014). Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid Redox Signal 20(7): 1098-1116.
  55. Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P. L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., Bizet, C., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Opolon, P., Yessaad, N., Vivier, E., Ryffel, B., Elson, C. O., Dore, J., Kroemer, G., Lepage, P., Boneca, I. G., Ghiringhelli, F. and Zitvogel, L. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342(6161): 971-976.
  56. Rébé, C., Végran, F., Berger, H. and Ghiringhelli, F. (2013). STAT3 activation: A key factor in tumor immunoescape. JAKSTAT 2(1): e23010.
  57. Darlix, A., Baumann, C., Lorgis, V., Ghiringhelli, F., Blonski, M., Chauffert, B., Zouaoui, S., Pinelli, C., Rech, F., Beauchesne, P. and Taillandier, L. (2013). Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res 33(8): 3467-3474.
  58. Delmas, D., Aires, V., Colin, D. J., Limagne, E., Scagliarini, A., Cotte, A. K. and Ghiringhelli, F. (2013). Importance of lipid microdomains, rafts, in absorption, delivery, and biological effects of resveratrol. Ann N Y Acad Sci 1290: 90-97.
  59. Végran, F., Berger, H., Ghiringhelli, F. and Apetoh, L. (2013). Socs3 induction by PPARgamma restrains cancer-promoting inflammation. Cell Cycle 12(14): 2157-2158.
  60. Ghiringhelli, F., Bruchard, M. and Apetoh, L. (2013). Immune effects of 5-fluorouracil: Ambivalence matters. Oncoimmunology 2(3): e23139.
  61. Bugaut, H., Bruchard, M., Berger, H., Derangère, V., Odoul, L., Euvrard, R., Ladoire, S., Chalmin, F., Vegran, F., Rébé, C., Apetoh, L., Ghiringhelli, F. and Mignot, G. (2013). Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One 8(6): e65181.
  62. Hervieu, A., Mignot, G. and Ghiringhelli, F. (2013). Dacarbazine mediate antimelanoma effects via NK cells. Oncoimmunology 2(4): e23714.
  63. Wiazzane, N., Chauffert, B. and Ghiringhelli, F. (2013). Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol 37(6): 614-618.
  64. Mitry, E., Rollot, F., Jooste, V., Guiu, B., Lepage, C., Ghiringhelli, F., Faivre, J. and Bouvier, A. M. (2013). Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer 49(13): 2919-2925.
  65. Berger, H., Végran, F., Chikh, M., Gilardi, F., Ladoire, S., Bugaut, H., Mignot, G., Chalmin, F., Bruchard, M., Derangère, V., Chevriaux, A., Rébé, C., Ryffel, B., Pot, C., Hichami, A., Desvergne, B., Ghiringhelli, F. and Apetoh, L. (2013). SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth. Cancer Res 73(12): 3578-3590.
  66. Ghiringhelli, F. and Apetoh, L. (2013). Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies. Future Oncol 9(4): 469-472.
  67. Pagès, P. B., Facy, O., Mordant, P., Ladoire, S., Magnin, G., Lokiec, F., Ghiringhelli, F. and Bernard, A. (2013). Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig model. PLoS One 8(3): e59485.
  68. Aires, V., Limagne, E., Cotte, A. K., Latruffe, N., Ghiringhelli, F. and Delmas, D. (2013). Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res 57(7): 1170-1181.
  69. Ghiringhelli, F., Isambert, N. and Ladoire, S. (2013). Degarelix as a new antiangiogenic agent for metastatic colon cancer? World J Gastroenterol 19(5): 769-772.
  70. Pierre, A. S., Minville-Walz, M., Fèvre, C., Hichami, A., Gresti, J., Pichon, L., Bellenger, S., Bellenger, J., Ghiringhelli, F., Narce, M. and Rialland, M. (2013). Trans-10, cis-12 conjugated linoleic acid induced cell death in human colon cancer cells through reactive oxygen species-mediated ER stress. Biochim Biophys Acta 1831(4): 759-768.
  71. Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., Kanellopoulos, J., Martin, F., Rébé, C., Apetoh, L. and Ghiringhelli, F. (2013). Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1): 57-64.
2 Protocols published
Liquid Luminescent DNA-precipitation Assay
Working on transcription factors requires studying interactions between protein and DNA. After identification of putative binding-sequences and motifs, Electrophoretic Mobility Shift Assay (EMSA) experiment is classically used to determine specific ...
Proximity Ligation Assay (PLA) Protocol Using Duolink® for T Cells
Protein-protein interaction experiments, such as co-immunoprecipitation (IP) assays, classically require tremendous amount of cells. This becomes a problem when your work focuses on rare cell populations (e.g., lymphocyte subtypes). O-link ...